DNA & Genetics C-Suite Shakeup, Phase III Plans Jolt Cardiff InvestorsBy adminFebruary 1, 20260 Cardiff Oncology (NASDAQ: CRDF) this past week trumpeted positive data via press release from a Phase II trial of its…
